<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19 adenovirus vector vaccines (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19 adenovirus vector vaccines (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">COVID-19 adenovirus vector vaccines (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="130896" href="/d/html/130896.html" rel="external">see "COVID-19 adenovirus vector vaccines (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55550123"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Janssen COVID-19 Vaccine [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55550487"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AstraZeneca COVID-19 Vaccine [DSC];</li>
<li>Covishield [DSC];</li>
<li>Jcovden [DSC];</li>
<li>Vaxzevria [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55555094"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vaccine;</li>
<li>
                        Vaccine, Adenovirus Vector;</li>
<li>
                        Vaccine, COVID-19</li></ul></div>
<div class="block doa drugH1Div" id="F55555102"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1816035d-6a14-4ee1-9e09-06e166640b6c">COVID-19 prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19 prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Janssen COVID-19 Vaccine [Canadian product]: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> The Janssen COVID-19 Vaccine emergency use authorization (EUA) for active immunization to prevent COVID-19 in the United States has been revoked as of June 1, 2023.</p>
<p style="text-indent:-2em;margin-left:6em;">The National Advisory Committee on Immunization (NACI) prefers mRNA and subunit COVID-19 vaccines; adenovirus vector vaccines may be offered only when all other COVID-19 vaccines are contraindicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HealthCanada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HealthCanada.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Primary </i>
<i>dose:</i>
<b>IM: </b>0.5 mL as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HealthCanada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HealthCanada.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">For patients who are moderately to severely immunocompromised:</p>
<p style="text-indent:-2em;margin-left:10em;">• If received a single dose of Janssen for the primary series, administer a second (additional) dose using an mRNA COVID-19 vaccine (eg, Pfizer or Moderna) ≥4 weeks after the Janssen dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Booster dose:</i> Bivalent Omicron-containing mRNA COVID-19 vaccines are recommended for booster doses; see NACI guidelines for more information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HealthCanada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HealthCanada.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>AstraZeneca COVID-19 Vaccine [Canadian product]:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> mRNA and subunit COVID-19 vaccines are preferred; adenovirus vector vaccines may be offered only when all other COVID-19 vaccines are contraindicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HealthCanada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HealthCanada.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Primary series: </i>
<b>IM: </b>0.5 mL per dose for 2 doses administered 28 to 84 days (4 to 12 weeks) apart. <b>Note:</b> The Canadian National Advisory Committee on Immunization (NACI) recommends an mRNA COVID-19 vaccine as the preferred second dose (≥28 days after the first dose) of a series initiated with AstraZeneca COVID-19 Vaccine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HealthCanada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HealthCanada.1'])">Ref</a></span>). For primary series consisting of 2 doses of AstraZeneca COVID-19 Vaccine, the WHO recommends an interval of 56 to 84 days (8 to 12 weeks) between doses due to increased efficacy and immunogenicity observed with a longer dose interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Additional primary series dose: </i>An additional (third) primary series dose may be offered to moderately to severely immunocompromised individuals ≥28 days after the second dose ONLY when other authorized COVID-19 vaccines (ie, mRNA vaccines) are contraindicated or inaccessible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HealthCanada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HealthCanada.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Booster dose:</i> Bivalent Omicron-containing mRNA COVID-19 vaccines are recommended for booster doses; see NACI guidelines for more information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HealthCanada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HealthCanada.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55555104"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F55555105"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F55555103"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55559981"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<p style="text-indent:0em;">
<b>Janssen: Note:</b> The Janssen COVID-19 Vaccine has been discontinued in the United States.</p>
<p style="text-indent:0em;">
<b>JCovden (Canadian product): </b></p>
<div class="collapsible">
<span class="collapsible-title">Capillary leak syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases (including fatal cases) of<b> capillary leak syndrome</b> (CLS) have been reported rarely. Some cases have occurred in patients with a history of CLS; patients with a known history of CLS should not receive the vaccine. CLS symptoms include acute episodes of limb edema, hypotension, hemoconcentration, and hypoalbuminemia and require prompt medical attention and treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; within the first days after vaccination.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, including <b>anaphylaxis</b>, have been reported with the JCovden COVID-19 Vaccine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Janssen.1'])">Ref</a></span>). Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Immune thrombocytopenia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia</b> with very low platelet levels &lt;20,000 per µL (including bleeding and fatal outcomes in some cases), has been reported very rarely with the JCovden COVID-19 Vaccine. Patients with neurological symptoms (including severe or persistent headaches, blurred vision, confusion, or seizure), persistent abdominal pain, chest pain, leg pain or swelling, shortness of breath, spontaneous bleeding, unusual skin bruising, or petechiae beyond the site of vaccination should seek immediate medical care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Janssen.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Intermediate: most cases occur within 4 weeks after vaccination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Janssen.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of immune thrombocytopenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Janssen.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurologic events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Demyelinating disorders, including<b> Guillain-Barre syndrome</b> and <b>transverse myelitis</b>, have been reported with the JCovden COVID-19 Vaccine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Janssen.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombosis with thrombocytopenia syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thrombosis with <b>thrombocytopenia</b> syndrome (TTS) (including bleeding and fatal outcomes in some cases), which clinically mimics autoimmune heparin-induced thrombocytopenia, has been reported very rarely with the JCovden COVID-19 Vaccine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36247442','lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36247442','lexi-content-ref-Janssen.1'])">Ref</a></span>). Thrombotic events included <b>cerebral sinus thrombosis</b>, <b>thrombosis</b> of the splanchnic-vein, and <b>arterial thrombosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36247442','lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36247442','lexi-content-ref-Janssen.1'])">Ref</a></span>). Most cases have occurred in females between the ages of 30 to 49 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Janssen.1'])">Ref</a></span>). Patients with neurological symptoms (including severe or persistent headaches or blurred vision), persistent abdominal pain, chest pain, leg swelling, shortness of breath, spontaneous bleeding, unusual skin bruising, or petechiae beyond the site of vaccination should seek immediate medical care.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Not clearly established; may be immune-mediated. Vaccine-induced platelet-activating antibodies against platelet factor 4 (PF4) may be present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36247442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36247442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Intermediate; most cases occur within 3 weeks after vaccination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Janssen.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females between the ages of 30 and 49 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Janssen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Janssen.1'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:0em;">
<b>Vaxzevria (Canadian product):</b></p>
<div class="collapsible">
<span class="collapsible-title">Capillary leak syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases (including fatal cases) of<b> capillary leak syndrome</b> (CLS) have been reported rarely. Some cases have occurred in patients with a history of CLS; patients with a known history of CLS should not receive the vaccine. CLS symptoms include acute episodes of limb edema, hypotension, hemoconcentration, and hypoalbuminemia and require prompt medical attention and treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; within the first days after vaccination.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Local reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Local reactions have been reported and include <b>erythema at injection site, induration at injection site, injection site pruritus, pain at injection site, swelling at injection site,</b>
<b>tenderness at injection site</b>, and <b>warm sensation at injection site</b>. Local reactions were reported more frequently in younger patients (18 to 64 years of age) compared to patients ≥65 years of age with the Vaxzevria COVID-19 Vaccine (adenovirus vector) [Canadian product]; frequency of local reactions was also higher after the first dose compared to the second dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vaxzevria.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vaxzevria.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; within 7 days after either injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vaxzevria.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vaxzevria.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Systemic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Systemic reactions have been reported and include <b>arthralgia, asthenia, chills, decreased appetite, fatigue, fever, headache, malaise, myalgia, nausea</b>, and <b>vomiting</b>. Systemic reactions were reported more frequently in younger patients (18 to 64 years of age) compared to patients ≥65 years of age with the Vaxzevria COVID-19 Vaccine (adenovirus vector) [Canadian product]; frequency of systemic reactions was also higher after the first dose compared to the second dose. One case of severe fever (40.5°C) (possibly related to vaccine) was reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vaxzevria.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vaxzevria.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; within 7 days after either injection. Severe fever: In the single case reported, onset was 2 days after the first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vaxzevria.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vaxzevria.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombosis with thrombocytopenia syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombosis</b> with new onset <b>thrombocytopenia</b> syndrome (TTS), which clinically mimics autoimmune heparin-induced thrombocytopenia, has been reported rarely with the Vaxzevria COVID-19 Vaccine (adenovirus vector) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36247442','lexi-content-ref-Vaxzevria.1','lexi-content-ref-33835769','lexi-content-ref-33835768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36247442','lexi-content-ref-Vaxzevria.1','lexi-content-ref-33835769','lexi-content-ref-33835768'])">Ref</a></span>). Thrombotic events (including fatal cases) included <b>cerebral sinus thrombosis </b>(in some cases accompanied by <b>cerebral hemorrhage)</b>, <b>portal vein thrombosis</b>, <b>pulmonary embolism</b>, <b>thrombosis</b> of the splanchnic-vein, and <b>arterial thrombosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36247442','lexi-content-ref-Vaxzevria.1','lexi-content-ref-33835769','lexi-content-ref-33835768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36247442','lexi-content-ref-Vaxzevria.1','lexi-content-ref-33835769','lexi-content-ref-33835768'])">Ref</a></span>). <b>Disseminated intravascular coagulation</b> has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33835769','lexi-content-ref-33835768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33835769','lexi-content-ref-33835768'])">Ref</a></span>). In one review, the median age was 36 (range: 22 to 49 years) and most reported cases occurred in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33835769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33835769'])">Ref</a></span>). In another study, the median age was 48 (range: 18 to 79 years) with no sex predominance or medical risk factors identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34379914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34379914'])">Ref</a></span>). More cases of TTS were reported after the first dose compared to the second dose. Patients with neurological symptoms (including severe or persistent headaches, blurred vision, confusion, or seizures), persistent abdominal pain, chest pain, leg swelling, shortness of breath, or petechiae or unusual bruising beyond the site of vaccination should seek immediate medical care. Patients who experience major arterial or venous thrombosis with thrombocytopenia with the Vaxzevria COVID-19 Vaccine should not receive a second dose of the Vaxzevria COVID-19 Vaccine. Treatment may differ from management of other thromboses; consult current guidance and hematology specialists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vaxzevria.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vaxzevria.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Not clearly established; may be immune-mediated. Vaccine-induced platelet-activating antibodies against platelet factor 4 (PF4) may be present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36247442','lexi-content-ref-33835769','lexi-content-ref-33835768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36247442','lexi-content-ref-33835769','lexi-content-ref-33835768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; most cases occurred within the first 3 weeks after vaccination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vaxzevria.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vaxzevria.1'])">Ref</a></span>). In one review describing 11 patients, cases occurred 5 to 16 days after vaccination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33835769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33835769'])">Ref</a></span>). In another study describing 170 definite and 50 probable cases of VITT, onset occurred 5 to 48 days (median 14) after vaccination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34379914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34379914'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55559979"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse reactions and incidences are derived from the product information for the JCovden and Vaxzevria COVID-19 Vaccines (adenovirus vector [Canadian products]), unless otherwise specified. Refer to Canadian product information for respective products for information regarding reporting adverse reactions (JCovden Canadian product monograph; Vaxzevria Canadian product monograph). Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>JCovden (Canadian product):</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Nausea (13% to 20%)<span class="lexi-table-link-container"> (<a aria-label="NauseaJCov table link" class="lexi-table-link" data-table-id="lexi-content-nauseajcov" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nauseajcov')">table 1</a>)</span><span class="table-link" style="display:none;">NauseaJCov</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="NauseaJCov" frame="border" id="lexi-content-nauseajcov" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [JCovden]): Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18 to 59 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,450</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,058</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥60 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,860</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,696</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Local: Pain at injection site (38% to 65%)<span class="lexi-table-link-container"> (<a aria-label="PainJCov table link" class="lexi-table-link" data-table-id="lexi-content-painjcov" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-painjcov')">table 2</a>)</span><span class="table-link" style="display:none;">PainJCov</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="PainJCov" frame="border" id="lexi-content-painjcov" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [JCovden]): Adverse Reaction: Pain at Injection Site</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">65%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18 to 59 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,450</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,058</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥60 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,860</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,696</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Fatigue (32% to 52%)<span class="lexi-table-link-container"> (<a aria-label="FatigueJCov table link" class="lexi-table-link" data-table-id="lexi-content-fatiguejcov" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatiguejcov')">table 3</a>)</span><span class="table-link" style="display:none;">FatigueJCov</span>, headache (32% to 50%)<span class="lexi-table-link-container"> (<a aria-label="HeadacheJCov table link" class="lexi-table-link" data-table-id="lexi-content-headachejcov" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headachejcov')">table 4</a>)</span><span class="table-link" style="display:none;">HeadacheJCov</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="FatigueJCov" frame="border" id="lexi-content-fatiguejcov" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [JCovden]): Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">52%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18 to 59 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,450</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,058</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥60 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,860</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,696</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="HeadacheJCov" frame="border" id="lexi-content-headachejcov" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [JCovden]): Adverse Reaction: Headache</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">50%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18 to 59 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,450</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,058</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥60 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,860</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,696</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Myalgia (26% to 46%)<span class="lexi-table-link-container"> (<a aria-label="MyalgiaJCov table link" class="lexi-table-link" data-table-id="lexi-content-myalgiajcov" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-myalgiajcov')">table 5</a>)</span><span class="table-link" style="display:none;">MyalgiaJCov</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="MyalgiaJCov" frame="border" id="lexi-content-myalgiajcov" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [JCovden]): Adverse Reaction: Myalgia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">46%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18 to 59 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,450</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,058</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥60 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,860</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,696</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Erythema at injection site (4% to 9%)<span class="lexi-table-link-container"> (<a aria-label="ErythemaJCov table link" class="lexi-table-link" data-table-id="lexi-content-erythemajcov" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-erythemajcov')">table 6</a>)</span><span class="table-link" style="display:none;">ErythemaJCov</span>, swelling at injection site (3% to 7%)<span class="lexi-table-link-container"> (<a aria-label="SwellingJCov table link" class="lexi-table-link" data-table-id="lexi-content-swellingjcov" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-swellingjcov')">table 7</a>)</span><span class="table-link" style="display:none;">SwellingJCov</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="ErythemaJCov" frame="border" id="lexi-content-erythemajcov" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [JCovden]): Adverse Reaction: Erythema at Injection Site</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18 to 59 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,450</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,058</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥60 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,860</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,696</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="SwellingJCov" frame="border" id="lexi-content-swellingjcov" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [JCovden]): Adverse Reaction: Swelling at Injection Site</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18 to 59 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,450</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,058</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥60 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,860</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,696</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Chills (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (2% to 10%)<span class="lexi-table-link-container"> (<a aria-label="FeverJCov table link" class="lexi-table-link" data-table-id="lexi-content-feverjcov" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-feverjcov')">table 8</a>)</span><span class="table-link" style="display:none;">FeverJCov</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="FeverJCov" frame="border" id="lexi-content-feverjcov" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [JCovden]): Adverse Reaction: Fever</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18 to 59 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,450</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,058</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥60 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,860</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,696</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary series</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%: Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Pericarditis</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Facial swelling, type IV hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia, cerebrovascular accident, complex regional pain syndrome, facial paresis, hemiparesis, malaise, myasthenia</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Limb pain</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vaxzevria (Canadian product):</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Nausea (8% to 22%)<span class="lexi-table-link-container"> (<a aria-label="NauseaVax table link" class="lexi-table-link" data-table-id="lexi-content-nauseavax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nauseavax')">table 9</a>)</span><span class="table-link" style="display:none;">NauseaVax</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="NauseaVax" frame="border" id="lexi-content-nauseavax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection-site pruritus (13%), pain at injection site (35% to 54%)<span class="lexi-table-link-container"> (<a aria-label="PainVax table link" class="lexi-table-link" data-table-id="lexi-content-painvax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-painvax')">table 10</a>)</span><span class="table-link" style="display:none;">PainVax</span>, tenderness at injection site (49% to 64%)<span class="lexi-table-link-container"> (<a aria-label="TendernessVax table link" class="lexi-table-link" data-table-id="lexi-content-tendernessvax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tendernessvax')">table 11</a>)</span><span class="table-link" style="display:none;">TendernessVax</span>, warm sensation at injection site (18%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="PainVax" frame="border" id="lexi-content-painvax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Pain at Injection Site</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">54%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">52%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="TendernessVax" frame="border" id="lexi-content-tendernessvax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Tenderness at Injection Site</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">64%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">62%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">49%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Chills (9% to 32%)<span class="lexi-table-link-container"> (<a aria-label="ChillsVax table link" class="lexi-table-link" data-table-id="lexi-content-chillsvax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-chillsvax')">table 12</a>)</span><span class="table-link" style="display:none;">ChillsVax</span>, fatigue (27% to 53%)<span class="lexi-table-link-container"> (<a aria-label="FatigueVax table link" class="lexi-table-link" data-table-id="lexi-content-fatiguevax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatiguevax')">table 13</a>)</span><span class="table-link" style="display:none;">FatigueVax</span>, headache (29% to 53%)<span class="lexi-table-link-container"> (<a aria-label="HeadacheVax table link" class="lexi-table-link" data-table-id="lexi-content-headachevax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headachevax')">table 14</a>)</span><span class="table-link" style="display:none;">HeadacheVax</span>, malaise (16% to 44%)<span class="lexi-table-link-container"> (<a aria-label="MalaiseVax table link" class="lexi-table-link" data-table-id="lexi-content-malaisevax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-malaisevax')">table 15</a>)</span><span class="table-link" style="display:none;">MalaiseVax</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="ChillsVax" frame="border" id="lexi-content-chillsvax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Chills</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="FatigueVax" frame="border" id="lexi-content-fatiguevax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">53%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="HeadacheVax" frame="border" id="lexi-content-headachevax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Headache</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">53%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="MalaiseVax" frame="border" id="lexi-content-malaisevax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Malaise</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (27%), myalgia (19% to 44%)<span class="lexi-table-link-container"> (<a aria-label="MyalgiaVax table link" class="lexi-table-link" data-table-id="lexi-content-myalgiavax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-myalgiavax')">table 16</a>)</span><span class="table-link" style="display:none;">MyalgiaVax</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="MyalgiaVax" frame="border" id="lexi-content-myalgiavax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Myalgia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Diarrhea (2%), vomiting (≤2%)<span class="lexi-table-link-container"> (<a aria-label="VomitingVax table link" class="lexi-table-link" data-table-id="lexi-content-vomitingvax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomitingvax')">table 17</a>)</span><span class="table-link" style="display:none;">VomitingVax</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="VomitingVax" frame="border" id="lexi-content-vomitingvax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Local: Erythema at injection site (1% to 3%)<span class="lexi-table-link-container"> (<a aria-label="ErythemaVax table link" class="lexi-table-link" data-table-id="lexi-content-erythemavax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-erythemavax')">table 18</a>)</span><span class="table-link" style="display:none;">ErythemaVax</span>, induration at injection site (≤3%)<span class="lexi-table-link-container"> (<a aria-label="IndurationVax table link" class="lexi-table-link" data-table-id="lexi-content-indurationvax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-indurationvax')">table 19</a>)</span><span class="table-link" style="display:none;">IndurationVax</span>, swelling at injection site (≤3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="ErythemaVax" frame="border" id="lexi-content-erythemavax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Erythema at Injection Site</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="IndurationVax" frame="border" id="lexi-content-indurationvax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Induration at Injection Site</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia (≥2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Limb pain (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Flu-like symptoms (≤1%), oropharyngeal pain (≥2%), rhinorrhea (≥2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (≤8%; feverishness: 34%)<span class="lexi-table-link-container"> (<a aria-label="FeverVax table link" class="lexi-table-link" data-table-id="lexi-content-fevervax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fevervax')">table 20</a>)</span><span class="table-link" style="display:none;">FeverVax</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="FeverVax" frame="border" id="lexi-content-fevervax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Fever</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,037</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,962</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">968</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose 2</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Hyperhidrosis, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain, decreased appetite<span class="lexi-table-link-container"> (<a aria-label="DecreasedAppVax table link" class="lexi-table-link" data-table-id="lexi-content-decreasedappvax" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreasedappvax')">table 21</a>)</span><span class="table-link" style="display:none;">DecreasedAppVax</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="DecreasedAppVax" frame="border" id="lexi-content-decreasedappvax" rules="all">
<caption style="text-align:center;">
<b>COVID-19 Vaccine (Adenovirus Vector [Vaxzevria]): Adverse Reaction: Decreased Appetite</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (MenACWY Vaccine, Placebo, or a Combination) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (COVID-19 Vaccine [Adenovirus Vector])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator [MenACWY Vaccine, Placebo, or a Combination])</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥18 years of age</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12,282</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11,962</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Dizziness, drowsiness, facial nerve paralysis (data insufficient to determine causal relationship), hypoesthesia, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Post-authorization (any adenovirus vector COVID-19 vaccine):</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Arterial thrombosis (including acute myocardial infarction and ischemic stroke) (Cari 2022), capillary leak syndrome, myocarditis, portal vein thrombosis (Greinacher 2021), pulmonary embolism (Greinacher 2021), thromboembolism (including deep vein thrombosis, pulmonary embolism, and transverse sinus thrombosis), thrombosis (splanchnic-vein and other) (Cari 2022, Greinacher 2021), vasculitis (small-vessel vasculitis with cutaneous manifestations)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Alopecia (Washrawirul 2022), ecchymoses (Washrawirul 2022), maculopapular rash (Washrawirul 2022), pruritus (Washrawirul 2022), psoriasis (Washrawirul 2022), skin rash (Washrawirul 2022), Sweet syndrome (Washrawirul 2022), urticaria (Washrawirul 2022)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Diarrhea, vomiting</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation (Greinacher 2021), immune thrombocytopenia (risk may be increased in the first 4 weeks after vaccination and in patients with a history of immune thrombocytopenia) (Cari 2022), lymphadenopathy, petechia (Washrawirul 2022), purpuric disease (Washrawirul 2022), thrombocytopenia (syndrome in combination with thrombosis [TTS]; also referred to as vaccine-induced [VITT]; or without thrombosis [risk may be increased in the first 4 weeks after vaccination]) (Cari 2022, CDC 2021d)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Anaphylaxis (Washrawirul 2022), angioedema (Washrawirul 2022), hypersensitivity angiitis</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Bell palsy, cerebral hemorrhage (Greinacher 2021; Schultz 2021), cerebral sinus thrombosis (with thrombocytopenia; or without thrombocytopenia [risk may be increased in the first 4 weeks after vaccination]) (Cari 2022), chronic inflammatory demyelinating polyneuropathy, dizziness, facial nerve paralysis, Guillain-Barre syndrome (Lee 2023), hypoesthesia, paresthesia, transverse myelitis</p>
<p style="text-indent:-2em;margin-left:6em;">Otic: Tinnitus</p></div>
<div class="block coi drugH1Div" id="F55555100"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of a severe allergic reaction (eg, anaphylaxis) after a previous dose or to a component of the formulation (eg, polysorbate 80); history of thrombosis with thrombocytopenia syndrome (TTS) following previous dose of Janssen COVID-19 Vaccine or any other adenovirus vector COVID-19 vaccine (eg, AstraZeneca COVID-19 Vaccine) (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: Additional contraindications (not in US labeling): </i>History of capillary leak syndrome.</p></div>
<div class="block war drugH1Div" id="F55559955"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis or tendinopathy) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. In general, it is recommended to defer vaccine administration in patients with moderate or severe acute illness (with or without fever) and to provide vaccination in patients with mild acute illness (with or without fever) (ACIP [Kroger 2022]). The Canadian product information for the AstraZeneca vaccine states to postpone vaccination in patients with acute severe febrile illness or acute infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding or hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2022]). For more information on administering the COVID-19 vaccine in patients with bleeding disorders, see society recommendations (eg, US National Hemophilia Foundation, World Federation of Hemophilia).</p>
<p style="text-indent:-2em;margin-left:4em;">• Guillain-Barré syndrome: The Janssen COVID-19 Vaccine has been associated with an increased risk of Guillain-Barré Syndrome (GBS). Not recommended in patients who developed GBS within 6 weeks after a dose of Janssen COVID-19 Vaccine; an mRNA COVID-19 vaccine should be used for subsequent doses. In patients who develop GBS ≥6 weeks following a dose of the Janssen vaccine, a bivalent mRNA vaccine should be strongly considered for any subsequent doses (CDC 2023a).</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune-mediated syndrome/thrombosis with thrombocytopenia syndrome: For primary immunization, persons with a history of immune-mediated syndrome characterized by thrombosis and thrombocytopenia (eg, heparin-induced thrombocytopenia) should receive an mRNA COVID-19 vaccine. For patients who developed thrombosis with thrombocytopenia syndrome (TTS) following the Janssen COVID-19 Vaccine (or another adenovirus vector COVID-19 vaccine), do not administer the Janssen vaccine; a bivalent mRNA vaccine booster dose is recommended in these patients ≥2 months after the initial Janssen vaccine dose and after stabilization of the clinical condition (CDC 2023a).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>• </i>Multisystem inflammatory syndrome: In patients with a history of multisystem inflammatory syndrome (MIS), it is typically recommended to delay COVID-19 vaccination until clinical recovery from MIS. For pediatric patients with MIS in children (MIS-C), deferral until ≥90 days after diagnosis is typically recommended. Data on the safety of COVID-19 vaccination following MIS-C or MIS in adults (MIS-A) are limited; risks and benefits should be weighed with consideration given to patient-specific factors (eg, recovery from illness [including normal cardiac function], risk of COVID-19). In pediatric patients who developed MIS-C within 90 days following a dose of COVID-19 mRNA vaccine, subsequent doses should be deferred, but may be offered on a case-by-case basis per provider discretion. In pediatric patients who developed MIS-C ≥90 days after a previous dose of COVID-19 mRNA vaccine, subsequent doses should be considered ≥90 days after MIS-C diagnosis for patients who have clinically recovered (including return to normal cardiac function) and who are at increased risk of COVID-19 exposure. For adults with MIS-A, decisions to administer further doses should be made in collaboration with expert healthcare providers; see CDC recommendations for details (CDC 2023a).</p>
<p style="text-indent:-2em;margin-left:4em;">• SARS-CoV-2 infection or exposure (CDC 2023a):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>- Persons with history of COVID-19 or asymptomatic SARS-CoV-2 infection:</i> Vaccination with an age-appropriate COVID-19 vaccine is recommended for everyone ≥6 months of age, regardless of history of symptomatic or asymptomatic SARS-CoV-2 infection. Persons who recently had SARS-CoV-2 infection may consider delaying vaccine doses by 3 months from symptom onset or positive test (if asymptomatic); increased time between infection and vaccination may improve vaccination immune response.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>- Persons with current SARS-CoV-2 infection (including asymptomatic): </i>In persons with known current SARS-CoV-2 infection, defer vaccination until the person has recovered from acute illness (if symptomatic) and no longer requires isolation. Persons who recently had SARS-CoV-2 infection may consider delaying vaccine doses by 3 months from symptom onset or positive test (if asymptomatic); increased time between infection and vaccination may improve vaccination immune response.</p>
<p style="text-indent:-2em;margin-left:6em;">- <i>Persons who received passive antibody COVID-19 therapy:</i> Vaccination does <b>not</b> need to be delayed for persons who previously received COVID-19 monoclonal antibody therapy or convalescent plasma (postexposure prophylaxis or treatment).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>- Persons with known SARS-CoV-2 exposure:</i> Persons with recent known exposure may be vaccinated if they do not have symptoms consistent with SARS-CoV-2 infection; follow CDC’s postexposure guidance. Vaccination for postexposure prophylaxis is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b>
<b>
<i></i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Clinicians administering vaccine should be aware of potential bleeding or hematoma that could occur due to IM administration (ACIP [Kroger 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Medications for postvaccination adverse reactions: Antipyretic or analgesic medications (eg, acetaminophen, nonsteroidal anti-inflammatory drugs) may be taken for the treatment of postvaccination local/systemic symptoms (if medically appropriate) but should not be used prophylactically to prevent postvaccination symptoms (CDC 2023a).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: The CDC and AAP recommend simultaneous administration of the COVID-19 vaccine with other vaccines or administration in the days before and after receipt of other vaccines (AAP 2022; CDC 2023a). When administering multiple vaccines, consider risks and benefits of each vaccine; administer each vaccine at a different injection site (at least 1 inch apart), and administer COVID-19 vaccine in a different limb than other vaccines that are more likely to cause a local reaction (CDC 2023a).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: COVID-19 vaccines can be safely administered to immunocompromised persons (including those with HIV or receiving immunosuppressant therapy) if no contraindications exist; as with the general population, mRNA vaccines are preferred. Immunocompromised persons may have a diminished immune response to the vaccine, but the potential benefit of the vaccine outweighs the uncertainties. Booster doses should be administered as appropriate for age and medical conditions. If possible, complete COVID-19 vaccination ≥2 weeks prior to initiation of immunosuppressive therapy (CDC 2023a; NACI 2023). For more information on administering COVID-19 vaccine in specific disease states, see society recommendations (eg, American Cancer Society, National Multiple Sclerosis Society).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some COVID-19 vaccines may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). See manufacturer's labeling. Polysorbate and polyethylene glycol are structurally related; cross-reactive hypersensitivity may occur (CDC 2023a).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2022]). Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2022]; CDC 2023a).</p>
<p style="text-indent:-2em;margin-left:4em;">• Mammograms: Temporary contralateral or ipsilateral lymphadenopathy after a COVID-19 vaccination has been reported. To avoid possible misinterpretation of mammogram screening, mammograms are recommended prior to vaccination or 4 to 6 weeks after the second dose. When this is not possible, the mammogram technologist or radiologist should be informed when and which vaccine was administered and what arm the injection was given (ACOG 2022). Imaging needed for acute symptoms, or urgent treatment planning or complications, should not be delayed (Becker 2021).</p></div>
<div class="block prod-avail drugH1Div" id="F58268046"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">The Janssen COVID-19 Vaccine emergency use authorization (EUA) for active immunization to prevent COVID-19 in the United States has been revoked as of June 1, 2023.</p></div>
<div class="block foc drugH1Div" id="F55550124"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Janssen COVID-19 Vaccine: 50 billion viral particles per 0.5 mL (2.5 mL [DSC]) [contains alcohol, usp, polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F55555093"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F55550488"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vaxzevria: 50 billion viral particles per 0.5 mL ([DSC]) [contains alcohol, usp, edetate (edta) disodium, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 billion viral particles per 0.5 mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jcovden: 50 billion viral particles per 0.5 mL ([DSC]) [contains alcohol, usp, polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F55559969"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Do not shake. For the Janssen product, gently swirl the vial in an upright position for 10 seconds before withdrawing each dose of vaccine. Administer IM in the deltoid muscle or anterolateral thigh (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HealthCanada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HealthCanada.1'])">Ref</a></span>). Use proper injection technique in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). To prevent syncope-related injuries, adolescents and adults should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">If administering simultaneously with other vaccines, administer each vaccine at a different injection site, at least 1 inch apart if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HealthCanada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HealthCanada.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients at risk for hemorrhage: </i>For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (≤23 gauge) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F55555097"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19 prevention (AstraZeneca [Vaxzevria] and Janssen COVID-19 Vaccines [Canadian products]): </b>Health Canada approved the AstraZeneca and Janssen COVID-19 Vaccines for active immunization to prevent COVID-19 in persons ≥18 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Canadian Guidance:</b> The National Advisory Committee on Immunization (NACI) has made recommendations on the use of COVID-19 vaccines; see recommendations for details (NACI 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The FDA Janssen COVID-19 Vaccine emergency use authorization (EUA) for active immunization to prevent COVID-19 in the United States has been revoked as of June 1, 2023. Refer to CDC for current COVID-19 guidance.</p></div>
<div class="block mst drugH1Div" id="F55558761"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Similarity of COVID-19 vaccine names may lead to confusion among products with subtle differences (eg, dosage volumes, dosing schedules, storage requirements, preparation for administration).</p>
<p style="text-indent:-2em;margin-left:4em;">COVID-19 vaccine may be confused with influenza virus vaccine. Medication errors have occurred when COVID-19 vaccine was inadvertently administered instead of influenza virus vaccine (and vice versa). These products may be stored in close proximity to each other. Confirm the correct vaccine has been selected prior to administration (ISMP/NAN 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">COVID-19 vaccine may be confused with epinephrine injection. Medication errors have occurred when epinephrine injection was inadvertently administered instead of COVID-19 vaccine. Most mix-ups were due to look-alike, predrawn syringes of epinephrine and the vaccine, which were stored in close proximity (ISMP [Smetzer 2022]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55343713"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55343710"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abatacept: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding SQ abatacept for 1 to 2 weeks after each vaccine dose and timing vaccine dose so that it is given 1 week prior to the next IV abatacept dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Administer COVID-19 vaccine 2 to 4 weeks prior to the next scheduled dose of anti-CD20 therapy, if used chronically for the treatment of autoimmune disease. Revaccinate 6 months after completion of anti-CD20 therapy if used over a limited period.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding apremilast for 1 to 2 weeks after vaccine administration as permitted by the underlying disease. These guidelines consider apremilast to be an immunomodulatory or immunosuppressive medication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding azathioprine for 1 to 2 weeks after each vaccine dose as permitted by the underlying disease. This recommendation is specific to patients using azathioprine for rheumatic and musculoskeletal disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding baricitinib, tofactinib, or upadacitinib for 1 to 2 weeks after vaccine administration as permitted by the underlying disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belimumab: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding subcutaneous belimumab doses for 1 to 2 weeks after each COVID-19 vaccine dose as disease activity permits. The recommendation specifies subcutaneous belimumab and does not mention intravenous belimumab.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcineurin Inhibitors (Systemic): May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding calcineurin inhibitors for 1 to 2 weeks after each vaccine dose as permitted by the underlying disease. This is specific to the use of calcineurin inhibitors for rheumatologic or musculoskeletal disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CAR-T Cell Immunotherapy: May diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: The CDC recommends that CAR-T-cell recipients who received COVID-19 vaccine prior to or during treatment with CAR-T-cell therapy should be revaccinated with a primary mRNA vaccine series at least 3 months (12 weeks) after CAR-T-cell therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: COVID-19 Vaccines may enhance the adverse/toxic effect of CloZAPine. COVID-19 Vaccines may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters)<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Adjust timing of intravenous cyclophosphamide so that administration occurs 1 week after each vaccine dose, if feasible; hold oral cyclophosphamide for 1 to 2 weeks after vaccine administration as permitted by the underlying disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding leflunomide for 1 to 2 weeks after vaccine administration as permitted by the underlying disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding methotrexate for 1 to 2 weeks after vaccine administration as permitted by underlying disease. This is specific to patients using methotrexate for rheumatic and musculoskeletal disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding mycophenolate for 1 to 2 weeks after each vaccine dose as permitted by the underlying disease. This recommendation is specific to patients using mycophenolate for rheumatic and musculoskeletal diseases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SulfaSALAzine: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding sulfasalazine for 1 to 2 weeks after vaccine administration as permitted by the underlying disease. These guidelines consider sulfasalazine to be an immunomodulatory or immunosuppressive medication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administration of inactivated vaccines is not recommended during the 2 weeks prior to teplizumab treatment, during therapy, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tixagevimab and Cilgavimab: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Wait at least 2 weeks after receipt of a COVID-19 vaccine before administering tixagevimab and cilgavimab for pre-exposure prophylaxis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding baricitinib, tofactinib, or upadacitinib for 1 to 2 weeks after vaccine administration as permitted by the underlying disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: May diminish the therapeutic effect of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding baricitinib, tofactinib, or upadacitinib for 1 to 2 weeks after vaccine administration as permitted by the underlying disease.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55559948"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The Janssen COVID-19 (adenovirus vector) Vaccine is no longer available in the United States (CDC 2023a).</p>
<p style="text-indent:0em;margin-top:2em;">Due to the risk of severe illness, pregnancy complications, and death from COVID-19 infection during pregnancy, staying current with COVID-19 vaccination is strongly recommended for all patients planning a pregnancy, patients trying to become pregnant now, and patients who might become pregnant in the future, including those patients previously diagnosed with COVID-19 infection (ACOG 2023; CDC 2023). Refer to current CDC guidelines for vaccination of adults.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to country-specific recommendations for AstraZeneca COVID-19 (adenovirus vector) Vaccine (not available in the United States.)</p></div>
<div class="block pri drugH1Div" id="F55559949"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The Janssen COVID-19 (adenovirus vector) Vaccine is no longer available in the United States (CDC 2023a).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of severe illness from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID. Pregnant patients with symptoms may require ICU admission, mechanical ventilation, or ventilatory support (ECMO) compared to symptomatic nonpregnant patients. Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG FAQ 2023; NIH 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Due to the risk of severe illness, pregnancy complications, and death from COVID-19 infection during pregnancy, staying current with COVID-19 vaccination is strongly recommended for pregnant patients (ACOG 2023; CDC 2023). Refer to current CDC guidelines for vaccination of adults.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to country-specific recommendations for AstraZeneca COVID-19 (adenovirus vector) Vaccine (not available in the United States).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor maternal and infant outcomes following exposure to COVID-19 vaccines during pregnancy is ongoing:</p>
<p style="text-indent:-2em;margin-left:4em;">Pregnant patients who are vaccinated with the Janssen COVID-19 Vaccine (adenovirus vector) vaccine are encouraged to enroll in the International Registry of Coronavirus Exposure in Pregnancy (IRCEP) (https://c-viper.pregistry.com/).</p></div>
<div class="block brc drugH1Div" id="F55559952"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if components of the Janssen COVID-19 (adenovirus vector) Vaccine are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The Janssen COVID-19 (adenovirus vector) Vaccine is no longer available in the United States (CDC 2023a).</p>
<p style="text-indent:-2em;margin-left:2em;">The risk of severe illness from COVID-19 infection is increased in recently pregnant patients compared to nonpregnant patients (ACOG FAQ 2023). Staying current with COVID-19 vaccination is recommended for all lactating patients who do not otherwise have contraindications to the vaccine (CDC 2023). Refer to current CDC guidelines for vaccination of adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to country-specific recommendations for AstraZeneca COVID-19 (adenovirus vector) Vaccine (not available in the United States).</p></div>
<div class="block mop drugH1Div" id="F55559971"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor for hypersensitivity and syncope for 15 minutes following administration (ACIP [Kroger 2022]). Observe patients for 30 minutes after vaccination in patients with the following: a history of nonsevere, immediate (within 4 hours) allergic reaction after receipt of a previous dose of COVID-19 vaccine; a history of anaphylaxis following receipt of a non–COVID-19 vaccine or injectable therapy; or a person with an allergy-related contraindication to a different type of COVID-19 vaccine (CDC 2023a). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Antibody testing to assess for SARS-CoV-2 immunity before or following vaccination is not currently recommended (CDC 2023a).</p></div>
<div class="block pha drugH1Div" id="F55559965"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Promotes active immunity against COVID-19 caused by SARS-CoV-2 virus. The adenovirus vector in the vaccine is a recombinant, replication-incompetent adenovirus vector that expresses the SARS-CoV-2 spike (S) antigen without virus propagation. The vaccine then elicits an immune response to the S antigen, which contributes to protection against COVID-19 disease. The Janssen vaccine contains a human adenovirus type 26 (Ad26) vector (FDA 2023). The AstraZeneca vaccine [Canadian product] contains a chimpanzee adenovirus (ChAdOx1) vector.</p></div>
<div class="block phk drugH1Div" id="F55559966"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Janssen COVID-19 Vaccine:</i> Vaccine efficacy assessment for moderate to severe/critical laboratory-confirmed COVID-19 and severe/critical COVID-19 was based on disease cases occurring from day 14 onward after the single dose. Vaccine efficacy assessment for severe/critical COVID-19 was based on cases occurring from day 28 onward after the single dose (FDA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AstraZeneca COVID-19 Vaccine [Canadian product]: </i>Protection was shown to begin ~3 weeks after the first dose.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522259"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Covishield | Vacina COVID-19 (recombinante) | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Convidecia</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Vacuna COVID-19 Janssen | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(CY)</span> <span class="country">Cyprus</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Covishield</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Covishield | Sputnik V | Sputnik V component 2</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Gam-COVID-Vac | Gam-COVID-Vac component 2 | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | KconecaVac</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Covishield | Janssen COVID-19 vaccine | Sputnik V | Sputnik V component 2</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Vaxzevria</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">AstraZeneca Korea Vaxzevria | COVID-19 vaccine Janssen | Korea AstraZeneca COVID-19 vaccine | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Vacuna COVID-19 Janssen | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Convidecia | COVID-19 vaccine AstraZeneca | Janssen COVID-19 vaccine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Covishield | Janssen COVID-19 vaccine | Sputnik V | Sputnik V component 2 | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(PA)</span> <span class="country">Panama</span><span class="countrySeparator">: </span><span class="drugName">Gam-COVID-Vac | Gam-COVID-Vac component 2 | Vacuna COVID-19 AstraZeneca</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | Vacuna COVID-19 AstraZeneca | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | Gam-COVID-Vac | Gam-COVID-Vac component 2 | Janssen COVID-19 vaccine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Convidecia | Covishield | Gam-COVID-Vac | Gam-COVID-Vac component 2 | PakVac</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Janssen COVID-19 vaccine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Vaxzevria</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Gam-COVID-Vac | Gam-COVID-Vac component 2 | Sputnik light</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">AstraZeneca COVID-19 vaccine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Jcovden | Vaxzevria</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Janssen COVID-19 vaccine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Sputnik V | Sputnik V component 2</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">AstraZeneca COVID-19 vaccine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine AstraZeneca | COVID-19 vaccine Janssen | Covishield</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">COVID-19 vaccine Janssen | Sputnik V</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP) Committee on Infectious Diseases. COVID-19 vaccines in infants, children, and adolescents. <i>Pediatrics</i>. Published online June 18, 2022. doi:10.1542/peds.2022-058700. https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2022-058700/188297/COVID-19-Vaccines-in-Infants-Children-and.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 vaccination considerations for obstetric–gynecologic care. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19. Updated September 25, 2023. Accessed September 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.2">
<a name="ACOG.2"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed September 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AstraZeneca.1">
<a name="AstraZeneca.1"></a>AstraZeneca COVID-19 vaccine (COVID-19 vaccine [ChAdOx1-S recombinant]) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; November 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33625298">
<a name="33625298"></a>Becker AS, Perez-Johnston R, Chikarmane SA, et al. Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: Radiology Scientific Expert Panel. <i>Radiology</i>. Published online February 24, 2021. doi:10.1148/radiol.2021210436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/33625298/pubmed" id="33625298" target="_blank">33625298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36247442">
<a name="36247442"></a>Cari L, Naghavi Alhosseini M, Bergamo A, et al. Thrombotic events with or without thrombocytopenia in recipients of adenovirus-based COVID-19 vaccines. <i>Front Cardiovasc Med</i>. 2022;9:967926. doi:10.3389/fcvm.2022.967926<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/36247442/pubmed" id="36247442" target="_blank">36247442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.4">
<a name="CDC.4"></a>Centers for Disease Control and Prevention (CDC). Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html" target="_blank"> https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html</a>. Updated September 15, 2023. Accessed September 18, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.6">
<a name="CDC.6"></a>Centers for Disease Control and Prevention (CDC). Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson &amp; Johnson) COVID-19 Vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients United States, April 2021. <i>MMWR Morb Mortal Wkly Rep</i>. 2021d;70(17):651-656. doi:10.15585/mmwr.mm7017e4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/33914723/pubmed" id="33914723" target="_blank">33914723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Cho CB. Adverse reactions to drugs. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24073903">
<a name="24073903"></a>Di Lernia V, Mansouri Y. Epstein-Barr virus and skin manifestations in childhood. <i>Int J Dermatol</i>. 2013;52(10):1177-1184. doi:10.1111/j.1365-4632.2012.05855.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/24073903/pubmed" id="24073903" target="_blank">24073903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33382671">
<a name="33382671"></a>Dooling K, Marin M, Wallace M, et al. The Advisory Committee on Immunization Practices' updated interim recommendation for allocation of COVID-19 vaccine - United States, December 2020. <i>MMWR Morb Mortal Wkly Rep</i>. 2021;69(5152):1657-1660. doi:10.15585/mmwr.mm695152e2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/33382671/pubmed" id="33382671" target="_blank">33382671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33301429">
<a name="33301429"></a>Dooling K, McClung N, Chamberland M, et al. The Advisory Committee on Immunization Practices' interim recommendation for allocating initial supplies of COVID-19 vaccine - United States, 2020. <i>MMWR Morb Mortal Wkly Rep</i>. 2020;69(49):1857-1859. doi:10.15585/mmwr.mm6949e1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/33301429/pubmed" id="33301429" target="_blank">33301429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32702298">
<a name="32702298"></a>Folegatti PM, Ewer KJ, Aley PK, et al; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet</i>. 2020;396(10249):467-478. doi:10.1016/S0140-6736(20)31604-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/32702298/pubmed" id="32702298" target="_blank">32702298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc (2003)</i>. 2013;53(1):102-103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33835769">
<a name="33835769"></a>Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. <i>N Engl J Med</i>. Published online April 9, 2021. doi:10.1056/NEJMoa2104840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/33835769/pubmed" id="33835769" target="_blank">33835769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2021">
<a name="ISMP.2021"></a>Institute for Safe Medication Practices (ISMP); The National Alert Network (NAN). Mix-ups between the influenza (flu) vaccine and COVID-19 vaccine. https://www.ismp.org/alerts/mix-ups-between-influenza-flu-vaccine-and-covid-19-vaccines. Published October 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47:313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.1">
<a name="Janssen.1"></a>JCovden (SARS-CoV-2 Vaccine [Ad26.COV2-S, recombinant]) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.2">
<a name="Janssen.2"></a>Janssen COVID-19 Vaccine (SARS-CoV-2 Vaccine) [prescribing information]. Horsham, PA: Janssen Biotech Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.2">
<a name="Janssen.2"></a>Janssen manufacturer communication March 8, 2021. Data on file.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.2">
<a name="Kroger.2"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Updated February 10, 2023. Accessed May 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36919452">
<a name="36919452"></a>Lee HY, Lien WC. Effects of COVID-19 vaccine type on Guillain-Barré syndrome: two cases and a literature review. <i>Hum Vaccin Immunother</i>. 2023;19(1):2171231. doi:10.1080/21645515.2023.2171231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/36919452/pubmed" id="36919452" target="_blank">36919452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43:172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33761987">
<a name="33761987"></a>Merchant HA. CoViD vaccines and thrombotic events: EMA issued warning to patients and healthcare professionals. <i>J Pharm Policy Pract</i>. 2021;14(1):32. doi:10.1186/s40545-021-00315-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/33761987/pubmed" id="33761987" target="_blank">33761987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HealthCanada.1">
<a name="HealthCanada.1"></a>National Advisory Committee on Immunization (NACI); Health Canada. COVID-19 vaccine: Canadian immunization guide. <a href="https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html" target="_blank">https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html</a>. Updated June 27, 2023. Accessed July 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline 183.https://www.nice.org.uk/guidance/cg183. Published September 3, 2014. Accessed March 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated April 20, 2023. Accessed May 15, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oliver.1">
<a name="Oliver.1"></a>Oliver SE, Gargano JW, Scobie H, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Janssen COVID-19 Vaccine — United States, February 2021.<i> MMWR Morb Mortal Wkly Rep</i>. 2021;70(9):329-332. <a href="https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7009e4-H.pdf" target="_blank">https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7009e4-H.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34379914">
<a name="34379914"></a>Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. <i>N Engl J Med</i>. 2021;10.1056/NEJMoa2109908. doi:10.1056/NEJMoa2109908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/34379914/pubmed" id="34379914" target="_blank">34379914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33440088">
<a name="33440088"></a>Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 Vaccine. <i>N Engl J Med</i>. Published online January 13, 2021. doi:10.1056/NEJMoa2034201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/33440088/pubmed" id="33440088" target="_blank">33440088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33835768">
<a name="33835768"></a>Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. <i>N Engl J Med</i>. Published online April 9, 2021. doi:10.1056/NEJMoa2104882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/33835768/pubmed" id="33835768" target="_blank">33835768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smetzer.2022">
<a name="Smetzer.2022"></a>Smetzer J, Cohen M, Shastay A, Jenkins R, Shultz K; Institute for Safe Medication Practices (ISMP). Start the year off right by addressing these Top 10 Medication Safety Concerns from 2021. <i>Acute Care ISMP Medication Safety Alert. </i>2022;27(2):1-5.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Fact sheet for healthcare providers administering vaccine: Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). <a href="https://www.fda.gov/media/146304/download" target="_blank">https://www.fda.gov/media/146304/download</a>. Updated March 13, 2023. Accessed March 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vaxzevria.1">
<a name="Vaxzevria.1"></a>Vaxzevria (Covid-19 Vaccine [ChAdOx1-S [recombinant]) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; May 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vaxzevria.1">
<a name="Vaxzevria.1"></a>Vaxzevria (Covid-19 Vaccine [ChAdOx1-S [recombinant]) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33306989">
<a name="33306989"></a>Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet</i>. 2021a;397(10269):99-111. doi:10.1016/S0140-6736(20)32661-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/33306989/pubmed" id="33306989" target="_blank">33306989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33617777">
<a name="33617777"></a>Voysey M, Clemens SAC, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet.</i> 2021b;397(10277):881-891. doi.org/10.1016/S0140-6736(21)00432-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/33617777/pubmed" id="33617777" target="_blank">33617777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35666609">
<a name="35666609"></a>Washrawirul C, Triwatcharikorn J, Phannajit J, Ullman M, Susantitaphong P, Rerknimitr P. Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: a systematic review and meta-analysis. <i>J Eur Acad Dermatol Venereol</i>. 2022;36(11):1947-1968. doi:10.1111/jdv.18294<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/covid-19-adenovirus-vector-vaccines-united-states-not-available-drug-information/abstract-text/35666609/pubmed" id="35666609" target="_blank">35666609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™). https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1. Updated March 15, 2022. Accessed May 13, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 130461 Version 133.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
